Sign up
Pharma Capital

The 'end of the marathon' for Motif Bio's Iclaprim

Vadim Alexandre, head of research at Northland Capital Partners, discusses with Proactive Motif Bio Plc's (LON:MTFB, NASDAQ: MTFB) lead drug, a next generation antibiotic, successfully negotiating a crucial final-stage clinical study.

The REVIVE-2 Phase III trial pitted Motif’s iclaprim treatment against vancomycin in patients with acute bacterial skin and skin structure infections (ABSSSI).


View full MTFB profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.